WT1-TCR engineered T cells

WT1-TCR engineered T cells are an adoptive cell therapy consisting of autologous or donor-derived T cells genetically modified to express a T-cell receptor (TCR) specific for the Wilms' Tumor Antigen 1 (WT1). WT1 is a transcription factor that is highly overexpressed in various hematological malignancies, such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), as well as solid tumors like ovarian cancer and glioblastoma. The engineered TCRs are typically HLA-restricted (most commonly HLA-A*02:01), allowing the T cells to recognize and eliminate tumor cells presenting WT1 peptides. Recent developments include the use of CRISPR-Cas9 gene editing to knock out inhibitory receptors like TIM-3 or LAG-3 to enhance efficacy within the immunosuppressive tumor microenvironment.

Other names

WT1-specific TCR-T cellsWT-1-specific TCR-T cellsWT 1-specific TCR-T cellsWT1-redirected T cellsWT-1-redirected T cellsWT 1-redirected T cellsWT1-TCR T cellsWT-1-TCR T cellsWT 1-TCR T cells